Solutions for Lipid Metabolism in TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology is committed to providing global collaborators with a full range of solutions and services for lipid metabolism in the tumor microenvironment (TME) to help you successfully achieve your research goals.
Lipids are classified into various subtypes based on their structural features or biological characteristics, including phospholipids, FAs, triglycerides, cholesterol, cholesteryl esters, sphingolipids, etc. In the tumor microenvironment (TME), tumor cells induce lipid metabolic reprogramming mainly by affecting the uptake, synthesis and catabolism of three major lipid molecules: fatty acids, phospholipids and cholesterol. On the one hand, lipid reprogramming allows tumor cells to produce more energy, which facilitates tumor cell survival in a nutrient-deprived microenvironment; on the other hand, lipid reprogramming generates signaling molecules that activate tumor-related signaling pathways, promoting tumor cell proliferation, invasion and metastasis . For example, tumor cells use glutamine and glucose-derived acetyl coenzyme A (coA) to synthesize large amounts of cholesterol and fatty acids to provide them with energy; meanwhile, metabolites produced during cholesterol synthesis and related factors regulating fatty acid synthesis can activate oncogenic signals.
The reprogramming of lipid metabolism in tumor cells interacts extremely closely with the tumor microenvironment (TME), and abnormalities in lipid uptake, synthesis and catabolism are closely related to tumorigenesis and progression. However, there are still many challenges in developing therapeutic strategies to target lipid metabolism, relying on lipid reprogramming mechanisms.
Alfa Oncology has established an innovative technology platform for tumor microenvironment center and is developing multiple technologies to provide high quality solutions and services to our global collaborators. In-depth studies of intracellular signaling of immune signals in the tumor microenvironment (TME) or intrinsic immunity / adaptive immune response / immune effector molecule related signaling, we expect to identify new targets and develop new approaches for combination therapy and reduction of side effects.
The application of lipidomics technology can reveal tumor-related lipid changes and find their abnormal metabolic pathways, and show a wide range of application prospects in the identification of tumor lipid biomarkers, early tumor diagnosis and the discovery of anti-tumor drug targets. For lipid metabolism in tumor microenvironment, Alfa Oncology can provide services of non-targeted lipidomics, targeted lipidomics, exosomal lipidomics, and MALDI imaging for lipidomics.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.